Abiopharma

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Inkoop van eigen aandelen

Acquisition of Own Shares

Waterstone Financial Declares Regular Quarterly Cash Dividend

IBP Recognized by David Weekley Homes as 2026 National Preferred Partner

Jack in the Box Inc. Completes $500 Million Securitized Financing Facility

Fiserv Announces Pricing of Tender Offers for Any and All of its Outstanding 5.150% Senior Notes due 2027 and 4.400% Senior Notes due 2049

Stanley Black & Decker Announces Release Date for Second Quarter 2026 Earnings

LP Building Solutions Breaks Ground on New LP® SmartSide® ExpertFinish® Manufacturing Facility in North Branch, Minnesota

SCWorx Receives Nasdaq Hearings Panel Decision Granting theCompany’s Request to Continue its Listing on the Nasdaq Stock Market, Subject to Compliance Conditions